CDK-inhibitors-associated kinase activity: A possible determinant of malignant potential in smooth muscle tumors of the external soft tissue

International Journal of Cancer

Volumn 94, Issue 3, 2001, Pages 353-362

  Dobashi, Yoh ^a,b   Noguchi, Takashi ^a   Nasuno, Shuji ^a   Katayama, Kazuhiro ^a   Kameya, Toru ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cdk inhibitors; Cell cycle; External soft tissue; Kinase activity; Smooth muscle tumors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P57;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOOTH MUSCLE; SOFT TISSUE CANCER;

CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MUSCLE NEOPLASMS; NUCLEAR PROTEINS; PHENOTYPE; PRECIPITIN TESTS; PROGNOSIS; RISK; SOFT TISSUE NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 0035501655     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1479     Document Type: Article

References (47)

1. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus
2. Epithelioid smooth-muscle tumors of the uterus: A clinicopathologic study of 18 patients
3. Gastrointestinal leiomyosarcomas: Experience of 14 cases and review of published reports
4. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical and electron microscopic study
5. Leiomyosarcoma of the skin and subcutaneous tissue
6. Leiomyoma of deep soft tissue. Clinicopathologic analysis of a series
7. The difficulty in predicting behavior of smooth-muscle tumors in deep soft tissue
8. Cutaneous pilar leiomyoma: Clinicopathologic analysis of 53 lesions in 45 patients
9. Cutaneous leiomyosarcoma
10. Abnormality of the p53, MDM2 and DCC genes in human leiomyosarcomas
11. Tumor suppressor genes and related molecules in leiomyosarcoma
12. Principles of CDK regulation
13. Inhibitors of mammalian G1 cyclin-dependent kinases
14. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21Cip1/WAF1 and p27Kip1
15. Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors
16. Primary leiomyosarcoma of bone: A clinicopathologic, immunohistochemical and ultra-structural study of 33 patients and a literature review
17. Active cyclin A-cdk2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas
18. Constitutive overexpression of cdk2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells
19. Persistent activation of cdk4 during neuronal differentiation of rat pheochromocytoma PC12 cells
20. Simultaneous suppression of cdc2 and cdk2 activities induces neuronal differentiation of PC12 cells
21. The long-term prognostic significance of the thymidine labeling index in breast cancer
22. Prognostic values of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level
23. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens
24. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
25. Mode of tumor extension and cell proliferation in adenocarcinomas of the lung
26. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: A prognostic factor independent of Ras
27. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
28. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies
29. Increased expression of the p27 KIP1 protein in human esophageal cancer cell lines that overexpress cyclin D1
30. Positive correlation between p27KIP1 expression and progression of human esophageal squamous cell carcinoma
31. p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas
32. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells
33. Reciprocal change in p27 (Kip1) and p21 (Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors
34. Ras- and mitogen-activated protein kinase kinase-dependent and -independent pathways in p2lCip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor and transforming growth factor-b1
35. Kip/Cip and INK4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-b
36. Phosphorylation at serine 10, a major phosphorylation site of p27Kipl, increases its protein stability
37. Differential interaction of the cyclin-dependent kinase (cdk) inhibitor p27 (Kipl) with cyclin A-cdk2 and cyclin D2-cdk4
38. Formation of p27-Cdk complexes during the human mitotic cell cycle
39. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27KIP1
40. p21-containing cyclin kinases exist in both active and inactive states
41. New functional activities for the p21 family of CDK inhibitors
42. Evidence for different modes of action of cyclin-dependent inhibitors: p15 and p16 binds to kinases, p21 and p27 bind to cyclins
43. Inhibition of cyclin-dependent kinases by p21
44. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
45. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
46. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas - Prognostic implications
47. Paradoxical correlations of cyclin-dependent kinases inhibitors p21waf1/cip1